Imunon reported raising $3.25 Million in an initial SEC Form D filing, from an offering of $3.25 Million
PUBLIC · IMNNMay 28, 2025
Amount Raised
$3.25 Million
$3.25 Million sold, per SEC Form D (first sale May 27, 2025)
Round Type
Seed
LawrencevilleBiotechnologyHealthcare
Quick answer
IMUNON raised $3.25 Million in a Seed round, dated May 27, 2025. IMUNON is based in Lawrenceville, New Jersey, United States.
How much did IMUNON raise?
IMUNON raised $3.25 Million in a Seed round on May 27, 2025.
What does IMUNON do?
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad..
Where is IMUNON based and how big is it?
IMUNON is based in Lawrenceville, New Jersey, United States. Fundz records about 24 employees.
Who are the decision-makers at IMUNON?
Fundz holds 2 contacts at IMUNON, including the BD Consultant. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who to call at IMUNON, and when
A new round usually means IMUNON is about to hire and buy. The teams that reach out first get the meeting.
An alert the day IMUNON raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at IMUNON, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at IMUNON. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
IMUNON
Location
Lawrenceville, New Jersey, United States
About
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment IMUNON raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.